Immune aging and cancer immunotherapy in experimental models
1Scope of investigation or explicitly identified community interest; not an established indication.
Immune
Thymulin
A zinc-dependent thymic peptide
Lab studiesImmune aging · cancer immunotherapy1
Investigational; this profile does not establish an approved use.
What does it do?
A zinc-dependent thymic hormone investigated for immune, inflammatory and pain-related effects; human therapeutic evidence is limited.
Approved & studied uses
Community uses Reported, unvalidated
Immune
17T-cell differentiation, suppressor-cell and NK activity.
Inflammation
17Cytokine/NF-kB, lung disease and inflammaging models.
Neural / aging
17Analgesia, neuroinflammation and thymic aging research.
Reasons people report using it; these do not establish benefit.17
Evidence limits
View research →Human treatment safety and cancer outcomes remain unestablished by the verified experiments.1
1 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Combination boundary
Mouse anti-PD-L1 combinations do not establish safety with human cancer immunotherapy.1
Investigational; this profile does not establish an approved use.
Amino-acid sequence
An exact sequence has not been verified for this formulation.
Reference identity · not independently confirmed17
Length9 amino acids
Molecular weight · Da858.86 Da (apo-thymulin); ~922 Da with zinc
Formula, sequence notation & identity
Thymic nonapeptide whose biological activity depends on zinc association
Sequence and formulation must be confirmed for the exact material; similarly named products are not necessarily interchangeable.
Pep-Pedia identity details
9 amino acids (nonapeptide) · 858.86 Da (apo-thymulin); ~922 Da with zinc
H-Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn-OH (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn)Reference description; checked chemical identity above takes precedence when available.17
Pharmacokinetics
How long does it stay in the body?
Unverified reference estimateNot independently confirmed
Reference half-life10 min16
Route / formulationSource page: Injectable. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 50 min
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Dardenne & Pleau 1994
Source’s reported peak time: 15 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Scope of evidence
Human treatment safety and cancer outcomes remain unestablished by the verified experiments.1
Reported timelines
Reference & communitySource expectations
No immediate change days 1–3; immune markers 1–2 weeks; animal pain effects within days, immune reconstitution months. Human timeline unestablished.17
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
Number of responses to this question: not disclosed.
Effectiveness
Number of responses to this question: not disclosed.
Side effects
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Source & limitations
The source displays “51 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Thymulin, thymalin and experimental analog PAT are different substances. Source compatibility labels are not clearance.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubcutaneous | 15 μg/100g body weight | Single dose or short course | Animal Research Protocol (Inflammation)Reference report | 5-10 days (based on thymic preparation protocols) | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Thymulin, thymalin and experimental analog PAT are different substances. Source compatibility labels are not clearance. Source route wording IP or SubQ Source tabs Injectable | |||||
| OtherIntraperitoneal | 15 μg/100g body weight | Single dose or short course | Animal Research Protocol (Inflammation)Reference report | 5-10 days (based on thymic preparation protocols) | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Thymulin, thymalin and experimental analog PAT are different substances. Source compatibility labels are not clearance. Source route wording IP or SubQ Source tabs Injectable | |||||
| OtherIP | 25-50 μg per rat (~100-200 μg/kg) | 30 min before inflammatory challenge | PAT Analog (Pain Research)Reference report | 5-10 days (based on thymic preparation protocols) | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Thymulin, thymalin and experimental analog PAT are different substances. Source compatibility labels are not clearance. Source tabs Injectable | |||||
| SubQ | 1-5 mg per injection | Once daily for 5-10 days | Anecdotal Human ProtocolReference report | 5-10 days (based on thymic preparation protocols) | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Thymulin, thymalin and experimental analog PAT are different substances. Source compatibility labels are not clearance. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 5-10 days (based on thymic preparation protocols)
- Break
- Monthly to quarterly cycles (anecdotal)
Reported timing
Very short half-life (~10 min in serum). Daily dosing during cycle recommended.
Side effects & safety
Combination boundary
Mouse anti-PD-L1 combinations do not establish safety with human cancer immunotherapy.
1Distinct identity
Thymulin and thymalin are different materials; the zinc-associated peptide is not the thymus extract.
1Unknown safety
Animal tolerability does not establish human safety; zinc requirement does not justify unmonitored supplementation.
Stop symptoms
Allergy, unexpected infections/autoimmune symptoms, severe local reactions or systemic illness.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Corticosteroids
Caution reportedImmune effects may differ.17
Reference report · Pep-Pedia label: Monitor CombinationZinc
Unverified pairingRequired binding cofactor; excess zinc has risks.17
Reference report · Pep-Pedia label: SynergisticThymosin Alpha-1
Unverified pairingUntested pairing.17
Reference report · Pep-Pedia label: CompatibleThymosin Beta-4
Unverified pairingUntested pairing.17
Reference report · Pep-Pedia label: CompatibleEpitalon
Unverified pairingUntested pairing.17
Reference report · Pep-Pedia label: CompatibleNSAIDs
Unverified pairingAnalog animal data, not combination proof.17
Reference report · Pep-Pedia label: CompatibleBPC-157
Unverified pairingNo interaction studies.17
Reference report · Evidence context: UnknownHumanin
Unverified pairingNo interaction studies.17
Reference report · Evidence context: UnknownAnti-PD-L1 immunotherapy
TheoreticalA 2026 mouse study found age-dependent combination effects. Human interaction safety and treatment benefit have not been established.1
Research contextNo matching interactions. Try another name or filter.
Reconstitution
A product-specific preparation or sterility protocol has not been verified.2
Dilution
A concentration calculation cannot establish a suitable diluent, compatibility, storage interval, or sterility. No universal bacteriostatic-water volume is assigned.2
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
The source reports a zinc-dependent peptide and distinguishes dry and mixed storage.
- Solvents mentioned
- Sterile water / Bacteriostatic water
- Reported parameters
- Dry material: reported −20°C. · Prepared solution: reported 2–8°C for 7–10 days.
The source describes gentle mixing and avoiding vigorous shaking.
The source’s zinc-intake suggestion is not evidence that supplementing zinc validates the preparation or its activity.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported variationZinc dependency criticalReported variationVery short half-lifeReported variationLimited human dataReported appearanceExcellent safety profile in studiesReported appearanceThird-party testing recommended
17Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Full storage notes from Pep-Pedia
17Lyophilized: -20°C. Reconstituted: 2-8°C, use within 7-10 days
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Research findings
PreclinicalSource context
Thymulin, thymalin and experimental analog PAT are different substances. Source compatibility labels are not clearance.
Compound identity & other names
Thymulin is a zinc-associated thymic peptide investigated in immune regulation. New 2026 work includes aged mice and human cells outside the body; this is not evidence for a human cancer or longevity regimen.
Other names: Serum thymic factor · FTS-Zn
Investigational; this profile does not establish an approved use.
How it may work
Zinc binding enables activity; proposed immune regulation includes T-cell/NK effects and inflammatory pathways.17
Immune aging in experimental models
Thymulin reduced inflammatory signaling and improved anti-PD-L1 response in selected mouse models. Clinical translation and human combination safety remain unresolved.
1Research areas and evidence gaps
Immune aging and cancer immunotherapy in experimental models. Scope of investigation or explicitly identified community interest; not an established indication.1
- Human treatment safety and cancer outcomes remain unestablished by the verified experiments.
- The evidence does not validate the identity, purity or handling of a separately sourced research product.
Community reports Unvalidated
Pep-Pedia reports use in the research-peptide community. These reports are not clinical evidence.2
Community protocol tables are unvalidated descriptions, not treatment instructions.
Search coverage and review status
Additional recent evidence was checked, including Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy. See individual source summaries for findings and limitations.
- Checked
- 2026-10-12
- Search
- thymulin 2025 2026 study
- Catalog
- Pep-Pedia ↗ · 13 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapyAbstract checked
AI-PREPARED SUMMARY
Aged mice and ex vivo human myeloid cells were studied, including mouse tumor models and anti-PD-L1 combinations.
Immune aging in experimental models
Thymulin reduced inflammatory signaling and improved anti-PD-L1 response in selected mouse models. Clinical translation and human combination safety remain unresolved.
Additional research · Checked 2026-10-12
2Pep-Pedia: ThymulinCommunity source checked
AI-PREPARED SUMMARY
Secondary community overview checked on 12 October 2026. Its practice tables and efficacy claims are not independently validated clinical guidance.
3Safieh-Garabedian, B., Poole, S., Allchorne, A., Kanaan, S., Saade, N., Bhutto, B. (2002). Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide in the rat. British Journal of Pharmacology, 136(6), 947-954.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The PAT analogue reduced inflammatory mediators and pain behavior in rats; it is distinct from unmodified thymulin.
Reported population / model
Rat
Reported study details
PAT analog · 1-200 μg IP · Endotoxin inflammation model
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
4Thymulin Treatment Attenuates Inflammatory Pain via Spinal Mechanisms (2019)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Inflamed rats had less heat hypersensitivity and swelling, with lower spinal microglial and inflammatory signaling.
Reported population / model
Rat
Reported study details
Thymulin IP · 21 days · CFA-induced inflammation
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Savino, W., Dardenne, M. (2010). Immunomodulatory role of thymulin in lung diseases. Annals of the New York Academy of Sciences, 1153, 217-226.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The review summarizes experimental lung-inflammatory effects; its broad no-toxicity claim does not establish safe human dosing.
Reported population / model
Review
Reported study details
Multiple models · Lung disease applications
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Dardenne, M., Pleau, J.M. (1994). Interactions between zinc and thymulin. Metal-Based Drugs, 1(2-3), 233-239.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The review describes zinc-dependent thymulin activity and its relation to zinc deficiency; replacement findings differ from peptide pharmacotherapy.
Reported population / model
Review
Reported study details
Zinc biology · CNRS Paris
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Safieh-Garabedian, B., Kanaan, S.A., Jalakhian, R.H., Poole, S., Jabbur, S.J., Saade, N.E. (2003). A thymulin analogue peptide with powerful inhibitory effects on pain of neurogenic origin. Neuroscience, 119(4), 1017-1025.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The PAT analogue altered nicotinic-receptor signaling and pain behavior in rats; comparisons with analgesics do not establish clinical equivalence.
Reported population / model
Rat
Reported study details
PAT analog · Electrophysiology · Neuropathy models
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Lunin, S.M., Novoselova, E.G. (2010). Thymus hormones as prospective anti-inflammatory agents. Expert Opinion on Therapeutic Targets, 14(8), 775-786.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
9Thomas-Vaslin, V., Cumberland, R., Goldrath, A.W., et al. (2020). Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging. Immunity & Ageing, 17, 2.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
10Dardenne, M., Pleau, J.M. (1994). Interactions between zinc and thymulin. Metal-Based Drugs, 1(2-3), 233-239.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
11Safieh-Garabedian, B., Poole, S., Allchorne, A., Kanaan, S., Saade, N., Bhutto, B. (2002). Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide in the rat. British Journal of Pharmacology, 136(6), 947-954.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
12Safieh-Garabedian, B., Kanaan, S.A., Jalakhian, R.H., Poole, S., Jabbur, S.J., Saade, N.E. (2003). A thymulin analogue peptide with powerful inhibitory effects on pain of neurogenic origin. Neuroscience, 119(4), 1017-1025.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
13Savino, W., Dardenne, M. (2010). Immunomodulatory role of thymulin in lung diseases. Annals of the New York Academy of Sciences, 1153, 217-226.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
14Lunin, S.M., Novoselova, E.G. (2010). Thymus hormones as prospective anti-inflammatory agents. Expert Opinion on Therapeutic Targets, 14(8), 775-786.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
15Thomas-Vaslin, V., Cumberland, R., Goldrath, A.W., et al. (2020). Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging. Immunity & Ageing, 17, 2.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
16Pep-Pedia: Thymulin — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 10 min and a peak time of 15 min. Stated attribution: Dardenne & Pleau 1994. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
17Pep-Pedia: Thymulin — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12